{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-121582","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.359488+00:00","generated_at":"2026-05-29T20:58:59.554630+00:00","sec_items":["1.01","3.02","5.02","8.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioXcel Therapeutics amends Oaktree credit deal, waives covenants, sets capital raise milestones, appoints director","bullets":["Fifth Amendment waives going concern and minimum revenue covenants; removes prior $50M raise requirement.","New capital milestones: $7M by Nov 27, $18M net by Mar 15, 2025, and $29M net by Aug 15, 2025.","Interest rate fixed at 13% (up from SOFR+7.5%) retroactive to Sep 30, 2024; 10% PIK option available.","Company must make $2.5M amortization payment by Dec 31, 2024; quarterly amortization at 5% begins Mar 31, 2026.","David Mack appointed to board; board expanded to 7. New warrants to lenders: 5M shares at $0.01/share."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-121582","json":"https://secwatch.observer/filing/0001104659-24-121582.json","markdown":"https://secwatch.observer/filing/0001104659-24-121582.md","text":"https://secwatch.observer/filing/0001104659-24-121582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924121582/0001104659-24-121582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924121582/tm2428677d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T20:58:59.554630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9432457be6","claim":"David Mack was appointed as Director at BioXcel Therapeutics, Inc..","evidence_excerpt":"On November 21, 2024, the Board appointed David Mack to the Board, effective as of November 21, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924121582/0001104659-24-121582-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}